{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:51:29Z","timestamp":1791906689048,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100293","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:30:36Z","timestamp":1787675436000},"page":"100293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine"],"prefix":"10.1016","volume":"3","author":[{"given":"James T.","family":"England","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5882-6070","authenticated-orcid":false,"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-9952","authenticated-orcid":false,"given":"Karen","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1662-6000","authenticated-orcid":false,"given":"Michelle","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Shamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Sabloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Christou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Houston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Landego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-1480","authenticated-orcid":false,"given":"Brian","family":"Leber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2119-6626","authenticated-orcid":false,"given":"Dina","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0579-6709","authenticated-orcid":false,"given":"Alejandro","family":"Garcia-Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"St-Hilaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nevill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9922-9232","authenticated-orcid":false,"given":"Amy","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Storring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elemary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Delage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Chodirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-1774","authenticated-orcid":false,"given":"Signy","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-3849","authenticated-orcid":false,"given":"Lee","family":"Mozessohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.bneo.2026.100293_bib1","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood.V114.22.2500.2500","article-title":"Transfusion dependence and low hemoglobin have the greatest impact on quality of life (QOL) in MDS patients-a tertiary care cross sectional and longitudinal study","volume":"114","author":"Buckstein","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2026.100293_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V110.11.817.817","article-title":"Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study","volume":"110","author":"Fenaux","year":"2007","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2026.100293_bib3","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100293_bib4","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","article-title":"Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2026.100293_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13148-022-01329-0","article-title":"Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line","volume":"14","author":"Aumer","year":"2022","journal-title":"Clin Epigenetics"},{"issue":"10","key":"10.1016\/j.bneo.2026.100293_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200034","article-title":"Low-dose decitabine versus low-dose azacitidine in lower-risk MDS","volume":"1","author":"Sasaki","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.bneo.2026.100293_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022015832","article-title":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100293_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clml.2014.04.010","article-title":"Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1392 participants","volume":"15","author":"Xie","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.bneo.2026.100293_bib9","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/j.clml.2021.01.024","article-title":"Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: a network meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bneo.2026.100293_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107040","article-title":"Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy","volume":"127","author":"Maurillo","year":"2023","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100293_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100293_bib12","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2026.100293_bib13","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100293_bib14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/14737140.2025.2544859","article-title":"Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence","volume":"25","author":"Zeidan","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.1016\/j.bneo.2026.100293_bib15","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1016\/j.clml.2022.04.023","article-title":"Patient preferences for benefits, risks, and administration route of hypomethylating agents in myelodysplastic syndromes","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 4","key":"10.1016\/j.bneo.2026.100293_bib16","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"Quality of life research within the EORTC\u2014the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer (1965)"},{"issue":"10","key":"10.1016\/j.bneo.2026.100293_bib17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100293_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.bneo.2026.100293_bib19","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100293_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/vox.12266","article-title":"Monthly blood transfusions decrease after four months of azacitidine","volume":"109","author":"Tseng","year":"2015","journal-title":"Vox Sang"},{"issue":"suppl_1","key":"10.1016\/j.bneo.2026.100293_bib21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2019-122980","article-title":"Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine\/decitabine) compared to IV decitabine","volume":"134","author":"Garcia-Manero","year":"2019","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026001044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026001044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:30:42Z","timestamp":1791905442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026001044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026001044"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100293","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100293"}}